Gene Involved In Hereditary Neuroendocrine Tumors Identified
By LabMedica International staff writers Posted on 21 Apr 2015 |
Image: Histopathology of a paraganglioma, a carotid body tumor (Photo courtesy of Nephron).
To date, 11 main genes whose mutations are responsible for pheochromocytomas and paragangliomas have been identified and of these, 6 are involved in cellular metabolism, more specifically, the Krebs cycle, which is the machinery used by cells to burn oxygen and obtain the energy required for cellular work.
Pheochromocytomas and paragangliomas are rare diseases, with an incidence of three to eight cases per million inhabitants, yet in spite of this low incidence, they represent a paradigm in hereditary cancer because they are the tumors with the highest hereditary predisposition. Approximately 50% of the patients inherit and/or transmit the susceptibility to developing this cancer.
Scientists at the Spanish National Cancer Research Centre (Madrid, Spain) and their colleagues have described the presence of mutations in the Malate Dehydrogenase 2 (MDH2) gene in a family with very rare neuroendocrine tumors associated with a high hereditary component. The tumors known as pheochromocytomas with groups of chromaffin cells in the central nervous system and paragangliomas with non-chromaffin or parasympathetic paragangliomas of glomus cells, affect the suprarenal and parathyroid glands, respectively.
The investigators sequenced the whole exome of one of the tumors in a patient with multiple malignant pheochromocytomas and paragangliomas using a HiSeq2000 system (Illumina; San Diego, CA, USA). This tumor showed no mutations in any of the 11 genes associated with genetic susceptibility to developing the disease. Analysis and filtering of the almost 80,000 variants found in the sample allowed the identification of a mutation in the MDH2 gene, whose association with this type of cancer had not been described before. Between 6- and 14-fold lower levels of MDH2 protein expression were observed in MDH2-mutated tumors compared with control patients.
The authors concluded that their study suggest efforts should be aimed at searching for new metabolic abnormalities in patients with these tumors. They explained that they were collaborating with the European Network for the Study of Adrenal Tumors consortium in order to continue investigating the role of MDH2 in the disease. Only in this way, due to the fact that these are rare diseases, will they be able to obtain a significant number of patients to whom they can translate the results. The study was published in the March 2015 issue of the Journal of the National Cancer Institute.
Related Links:
Spanish National Cancer Research Center
Illumina
Pheochromocytomas and paragangliomas are rare diseases, with an incidence of three to eight cases per million inhabitants, yet in spite of this low incidence, they represent a paradigm in hereditary cancer because they are the tumors with the highest hereditary predisposition. Approximately 50% of the patients inherit and/or transmit the susceptibility to developing this cancer.
Scientists at the Spanish National Cancer Research Centre (Madrid, Spain) and their colleagues have described the presence of mutations in the Malate Dehydrogenase 2 (MDH2) gene in a family with very rare neuroendocrine tumors associated with a high hereditary component. The tumors known as pheochromocytomas with groups of chromaffin cells in the central nervous system and paragangliomas with non-chromaffin or parasympathetic paragangliomas of glomus cells, affect the suprarenal and parathyroid glands, respectively.
The investigators sequenced the whole exome of one of the tumors in a patient with multiple malignant pheochromocytomas and paragangliomas using a HiSeq2000 system (Illumina; San Diego, CA, USA). This tumor showed no mutations in any of the 11 genes associated with genetic susceptibility to developing the disease. Analysis and filtering of the almost 80,000 variants found in the sample allowed the identification of a mutation in the MDH2 gene, whose association with this type of cancer had not been described before. Between 6- and 14-fold lower levels of MDH2 protein expression were observed in MDH2-mutated tumors compared with control patients.
The authors concluded that their study suggest efforts should be aimed at searching for new metabolic abnormalities in patients with these tumors. They explained that they were collaborating with the European Network for the Study of Adrenal Tumors consortium in order to continue investigating the role of MDH2 in the disease. Only in this way, due to the fact that these are rare diseases, will they be able to obtain a significant number of patients to whom they can translate the results. The study was published in the March 2015 issue of the Journal of the National Cancer Institute.
Related Links:
Spanish National Cancer Research Center
Illumina
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans